Breast cancer

Breast cancer remains one of the leading causes of cancer-related morbidity and mortality and demands approaches that integrate tumor control, modulation of the tumor microenvironment, and robust indicators for patient stratification. From a glycoimmunology perspective, we study how glyco-checkpoints and aberrant glycosylation—particularly involving galectin-1 (Gal-1)—promote immune evasion, aberrant angiogenesis, stromal remodeling, and resistance to immunotherapy and anti-angiogenic treatments, with a particularly strong impact in aggressive subtypes such as triple-negative breast cancer.

In parallel, we investigate how hormones and protein–glycan interactions shape antitumor immune responses, with the goal of improving response rates to immunotherapy in metastatic breast cancer, a major clinical challenge. Using preclinical models and patient cohorts, we aim to identify novel prognostic and predictive biomarkers and to establish new therapeutic interventions.